Dr Reddy’s Laboratories Ltd Share Price Target 2025 – Expert Analysis
The Indian pharmaceutical industry has always been a strong pillar for long-term investors. Among the leading names, Dr Reddy’s Laboratories Ltd stands tall with its global presence, innovative research, and consistent financial performance. In this article, we will break down the Dr Reddy’s Laboratories Ltd share price target, valuation metrics, recent performance, and what experts expect in 2025 and beyond.
Key Stock Highlights
- Current Price (22 Aug 2025): ₹1,277.60
- Intraday Range: ₹1,265.60 – ₹1,284.10
- 52-Week Range: ₹1,020 – ₹1,415
- Market Cap: ~₹1.06 lakh crore
- Dividend Yield: 0.63%
👉 The stock is currently trading about 9.7% below its 52-week high, which makes it attractive for long-term investors.
Valuation & Performance Metrics
| Metric | Value |
|---|---|
| P/E Ratio (TTM) | ~18.7 – 18.8× |
| P/B Ratio | ~3.1 – 3.5× |
| EPS (TTM) | ₹68.07 |
| Dividend Yield | 0.63% |
| 6-Month Return | +10.9% |
| 1-Year Return | –9.6% to –9.1% |
✅ With a P/E below 20, Dr Reddy’s trades at a reasonable valuation compared to global pharma peers.
Recent Price Movements
- 21 Aug 2025 (Thursday): Stock rallied 2.48% to ₹1,276.55, outperforming peers like Lupin and Zydus Lifesciences.
- 22 Aug 2025 (Friday): A minor gain of 0.04%, closing at ₹1,277.00 on lower-than-average trading volume.
📌 Such trends show a balance of institutional buying and profit booking.
Dr Reddy’s Laboratories Ltd Share Price Target 2025
Market analysts expect the following share price targets for Dr Reddy’s:
- Low Target: ₹990
- Median Target: ₹1,284
- High Target: ₹1,660
As per INDmoney analyst consensus, the average target is around ₹1,284, which is very close to the current price.
Technical Outlook
- Weekly Stochastic Crossover: Historically leads to +6.3% average gains within 7 weeks.
- 50-Day Moving Average Crossover: Suggests +3.5% average gain within 30 days.
- TradingView Signals: Indicate a “Strong Buy” in the short term.
📊 For technical traders, this signals bullish momentum in the near term.
Dividend & Earnings Outlook
- Final dividend of ₹8 per share was paid on 10 July 2025.
- Upcoming Q2 FY26 earnings announcement expected on 24 October 2025.
📌 Dividend yield may seem modest, but consistency makes Dr Reddy’s a stable dividend-paying stock.
Why Indian Investors Prefer Pharma Stocks
Pharma companies like Dr Reddy’s are considered defensive bets. Even during economic slowdowns, demand for medicines remains steady. For Indian investors, such stocks act as wealth protectors while offering long-term growth.
However, one must consider:
- USFDA regulations can impact exports.
- Currency fluctuations may affect profitability.
- Rising competition from both Indian and multinational peers.
Conclusion – Should You Buy Dr Reddy’s Laboratories Ltd?
The Dr Reddy’s Laboratories Ltd share price target 2025 indicates moderate upside with stable fundamentals. It is best suited for:
✔️ Long-term investors seeking steady growth
✔️ Investors looking for a defensive portfolio stock
✔️ Those who value dividend stability over high short-term returns
💡 If you are building a long-term Indian equity portfolio, Dr Reddy’s deserves serious consideration.
Call to Action
Would you like to explore more expert insights on Indian stocks?
👉 Read our latest guide on Best Stocks for Long-Term Investment in India
👉 Learn more with our SIP Calculator